Skip to main content

CORT

Stock
Health Care
Biotechnology

Performance overview

CORT Price
Price Chart

Forward-looking statistics

Beta
0.92
Risk
51.93%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Company info

SectorHealth Care
IndustryBiotechnology
Employees330
Market cap$3.5B

Fundamentals

Enterprise value$7.5B
Revenue$685.4M
Revenue per employee
Profit margin19.55%
Debt to equity1.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$1.15
Dividend per share
Revenue per share$6.62
Avg trading volume (30 day)$120M
Avg trading volume (10 day)$156M
Put-call ratio

Macro factor sensitivity

Growth+2.6
Credit+2.4
Liquidity-2.1
Inflation-1.1
Commodities+0.7
Interest Rates-1.7

Valuation

Dividend yield0.00%
PEG Ratio41.30
Price to sales11.18
P/E Ratio41.30
Enterprise Value to Revenue10.89
Price to book11.21

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day
Ex. dividend day

News

New Strong Sell Stocks for May 29th

CORT, AETUF and MITT have been added to the Zacks Rank #5 (Strong Sell) List on May 29, 2025.

Zacks Investment Research (May 29, 2025)
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast

Corcept Therapeutics Incorporated  CORT announced on Monday that the ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR).

Benzinga (March 31, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free